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RIPE Treatment Failure in a Patient with Mycobacterium tuberculosis sepsis
Mohamad Dabaja DO, Erica Herc MD
Department of Internal Medicine
Henry Ford Health System, Detroit, Michigan
Learning Objectives

Photos

1. Recognize TB sepsis

Traditional MTB therapy, RIPE, is the mainstay of treatment and
typically results in a high cure rates with high bioavailability (BA)
ranging from 89-100%. One consideration in patients who have
significant MTB disease burden and do not have clinical improvement
despite optimized MTB therapy is oral malabsorption of anti-TB drugs.

2. Evaluate for optimization of antimicrobial therapy in the setting of
TB sepsis with concern for absorption issues

Case Presentation

Blood levels of isoniazid and rifampin typically take several days to
result. A patient with severe disease cannot afford to delay care as it
can lead to a poor prognosis with MTB septic shock having an inhospital mortality of 79.2%(5). Instead, a surrogate using
acetaminophen levels (BA 85-98%) after scheduled dosing would be a
reasonable alternative. A patient who comes in with a sepsis picture
secondary to MTB may need to be converted to intravenous therapy
due to decreased gut absorption. The decision to implement this
practice early in the treatment algorithm to ensure proper drug blood
levels is an important clinical consideration.

A 36-year old Guatemalan male with diabetes mellitus presented with
night sweats, productive cough, worsening dyspnea, and chills for the
past 3 weeks. The patient had a remote history being incarcerated and
moved to the United States from Guatemala 12 years ago, with his last
visit being one year prior to current presentation.

At presentation, patient was febrile, hypotensive, tachycardic,
tachypneic, and was found to have acute respiratory failure with an
elevated lactate. A CT chest was obtained showing bilateral
consolidative changes predominantly in the upper lobes and scattered
nodule-like opacities with central cavitation. Initial infectious work-up
revealed a positive sputum MTB PCR. Rifampin resistance was not
detected. In addition, he was found to have co-infection with Influenza
B. The patient was started on rifampin, isoniazid, pyrazinamide,
ethambutol (RIPE), and oseltamivir.

Conclusion
Figure 1. 02/08/2020 (Day of presentation) Multifocal consolidations
and cavitary lesions

While on therapy, the patient remained hypotensive, febrile, and
hypoxic, requiring multiple transfers to the ICU in which he was placed
on a ventilator and vasopressors. Adrenal insufficiency work up was
negative. After 24 days of therapy, he continued to be
hemodynamically unstable despite a trial of broad spectrum antibiotics
and his MTB culture returning pansusceptible to all TB therapy. Repeat
Chest CT demonstrated previous findings without significant
improvement. Repeat AFB smear after 33 days of treatment still
yielded many acid-fast bacteria.

Though RIPE therapy is known to be the mainstay of therapy for MTB,
it may be less efficacious in a patient with sepsis and gut malabsorption
issues. The swift decision to convert from an oral to intravenous antiTB regimen after assessing absorption with acetaminophen levels is
something a clinician should consider in their medical decision
making.
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This prompted concern for absorption issues. HIV antigen/antibody
combo and RNA were obtained with a negative result. Testing for
rifampin and isoniazid blood levels requires a send out lab and takes
several days to result. Instead, acetaminophen (APAP) levels were done
to get a better idea about absorption. After multiple scheduled doses,
testing showed APAP blood levels <10.0 ug/ml, consistent with poor
absorption.
Patient’s therapy was switched to IV linezolid, IV moxifloxacin, IV
rifampin, and oral pyrazinamide, and isoniazid were continued. After
11 days into this treatment the patient no longer required supplemental
oxygen, was afebrile for >72hrs, and his blood pressure improved.

Discussion

Figure 2. 3/25/2020 (46 days later) Improvement in the multifocal

airspace process and cavitary regions. Note how the left normal
lung parenchyma is more visible now.

